Ignite Creation Date:
2024-05-06 @ 12:07 AM
Last Modification Date:
2024-10-26 @ 10:45 AM
Study NCT ID:
NCT01498003
Status:
COMPLETED
Last Update Posted:
2015-07-14
First Post:
2011-12-11
Brief Title:
Tirofiban in Stenting for Long Coronary Lesion
Sponsor:
Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PETITION
Brief Summary:
Periprocedural myonecrosis or infarction are associated with short intermediate and long term adverse outcomes Previous study indicated 126 of patients suffered a peri-procedural CK-MB rise by overlapping use of drug-eluting stents for long coronary lesions Here the investigators hypothesize that peri-procedural use of tirofiban could reduce the occurrence of periprocedural infarciton in elective patients with long coronary lesions treated by overlapping use of drug-eluting stents
Detailed Description:
According to the results of 126 occurrence of peri-procedural myocardial infarction after long stent implantation by previous reportInternational Journal of Cardiology 2009134 231-237 the investigator hypothesize the 50 reduction of peri-procedural MI by using tirofiban Three hundred and sixty-nine patients in each group are needed to reach 80 of power with α 005
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None